These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 8047295)
1. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Griffiths PD; Perry RH; Crossman AR Neurosci Lett; 1994 Mar; 169(1-2):68-72. PubMed ID: 8047295 [TBL] [Abstract][Full Text] [Related]
2. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831 [TBL] [Abstract][Full Text] [Related]
3. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Joyce JN; Murray AM; Hurtig HI; Gottlieb GL; Trojanowski JQ Neuropsychopharmacology; 1998 Dec; 19(6):472-80. PubMed ID: 9803423 [TBL] [Abstract][Full Text] [Related]
4. Neurotransmitter receptor alterations in Parkinson's disease. Reisine TD; Fields JZ; Yamamura HI Life Sci; 1977 Aug; 21(3):335-43. PubMed ID: 197361 [No Abstract] [Full Text] [Related]
5. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Mattila PM; Röyttä M; Lönnberg P; Marjamäki P; Helenius H; Rinne JO Acta Neuropathol; 2001 Aug; 102(2):160-6. PubMed ID: 11563631 [TBL] [Abstract][Full Text] [Related]
6. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941 [TBL] [Abstract][Full Text] [Related]
7. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Rinne JO; Laihinen A; Lönnberg P; Marjamäki P; Rinne UK Brain Res; 1991 Aug; 556(1):117-22. PubMed ID: 1834312 [TBL] [Abstract][Full Text] [Related]
9. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. Griffiths PD; Sambrook MA; Perry R; Crossman AR J Neurol Sci; 1990 Dec; 100(1-2):131-6. PubMed ID: 1965202 [TBL] [Abstract][Full Text] [Related]
10. Does loss of nerve growth factor receptors precede loss of cholinergic neurons in Alzheimer's disease? An autoradiographic study in the human striatum and basal forebrain. Strada O; Hirsch EC; Javoy-Agid F; Lehéricy S; Ruberg M; Hauw JJ; Agid Y J Neurosci; 1992 Dec; 12(12):4766-74. PubMed ID: 1464766 [TBL] [Abstract][Full Text] [Related]
11. Muscarinic receptor binding changes in postmortem Parkinson's disease. McOmish C; Pavey G; McLean C; Horne M; Dean B; Scarr E J Neural Transm (Vienna); 2017 Feb; 124(2):227-236. PubMed ID: 27873015 [TBL] [Abstract][Full Text] [Related]
12. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. Pierot L; Desnos C; Blin J; Raisman R; Scherman D; Javoy-Agid F; Ruberg M; Agid Y J Neurol Sci; 1988 Sep; 86(2-3):291-306. PubMed ID: 2975699 [TBL] [Abstract][Full Text] [Related]
13. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases. Joyce JN Brain Res; 1993 Jan; 600(1):156-60. PubMed ID: 8422582 [TBL] [Abstract][Full Text] [Related]
14. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015. Farkas S; Nagy K; Jia Z; Harkany T; Palkovits M; Donohou SR; Pike VW; Halldin C; Máthé D; Csiba L; Gulyás B Brain Res Bull; 2012 Apr; 87(6):504-10. PubMed ID: 22421165 [TBL] [Abstract][Full Text] [Related]
15. Coactivation of dopamine D1 and D2 receptors increases the affinity of cholecystokinin-8 receptors in membranes from post-mortem human caudate-putamen. von Euler G; Mailleux P; von Euler M; Schiffmann SN; Vanderhaeghen JJ; Fuxe K Brain Res; 1992 Jul; 584(1-2):157-62. PubMed ID: 1325243 [TBL] [Abstract][Full Text] [Related]
16. Reduction in striatal D2 dopamine receptor mRNA and binding following AF64A lesions. Narang N; Pundt LL; Hunt ME; Alburges ME; Wamsley JK Mol Chem Neuropathol; 1993 Sep; 20(1):81-96. PubMed ID: 8251034 [TBL] [Abstract][Full Text] [Related]
17. Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia. Dean B; Pavey G; Scarr E; Goeringer K; Copolov DL Life Sci; 2004 May; 74(25):3115-31. PubMed ID: 15081577 [TBL] [Abstract][Full Text] [Related]
18. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Graham WC; Sambrook MA; Crossman AR Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431 [TBL] [Abstract][Full Text] [Related]
19. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Kaufman MJ; Madras BK Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351 [TBL] [Abstract][Full Text] [Related]
20. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]